{
    "clinical_study": {
        "@rank": "159973", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to add 141W94 to an anti-HIV\n      regimen that includes retrovir plus epivir."
        }, 
        "brief_title": "A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a double-blind, placebo-controlled, two-arm study comparing treatment with a triple\n      regimen consisting of 141W94, retrovir, and epivir and a double regimen consisting of\n      retrovir and epivir."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  HIV-positive status.\n\n          -  Screening viral load >= 10,000 copies/mm3 14 days prior to entry.\n\n          -  CD4+ cell counts >= 200 cells/mm3 14 days prior to entry.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n        Clinical diagnosis of AIDS (CDC 1993 Classification C).\n\n        Concurrent Medication:\n\n        Excluded:\n\n        Terfenadine, astemizole, cisapride, triazolam, medazolam, and\n        ergotamine/dihydroergotamine-containing regimens.\n\n        Patients with the following prior conditions are excluded:\n\n        Clinically relevant hepatitis in the previous 6 months.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Greater than 4 weeks of any nucleoside antiretroviral therapy.\n\n          -  Previous therapy with an HIV protease inhibitor.\n\n          -  Cytotoxic chemotherapeutic agents within 4 weeks prior to entry.\n\n          -  Immunomodulating agents within 3 months prior to entry.\n\n        Prior Treatment:\n\n        Excluded:\n\n        Radiotherapy within 4 weeks prior to entry.\n\n        Risk Behavior:\n\n        Excluded:\n\n        Current alcohol or illicit drug use that may interfere with the patient's ability to\n        comply with the dosing schedule or protocol evaluations."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "290", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002195", 
            "org_study_id": "264D", 
            "secondary_id": "PROA3001"
        }, 
        "intervention": [
            {
                "intervention_name": "Amprenavir", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Lamivudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Zidovudine", 
                "Lamivudine", 
                "Reverse Transcriptase Inhibitors", 
                "Amprenavir", 
                "HIV Protease Inhibitors"
            ]
        }, 
        "keyword": [
            "Drug Therapy, Combination", 
            "Zidovudine", 
            "HIV Protease Inhibitors", 
            "Lamivudine", 
            "VX 478", 
            "Reverse Transcriptase Inhibitors", 
            "Anti-HIV Agents", 
            "Viral Load"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beverly Hills", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90211"
                    }, 
                    "name": "Pacific Oaks Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20037"
                    }, 
                    "name": "Dr Bruce Rashbaum"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Coral Gables", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33146"
                    }, 
                    "name": "Community Research Initiative of South Florida"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maitland", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32751"
                    }, 
                    "name": "Community Research Initiative of Central Florida"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "Univ of Miami School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60610"
                    }, 
                    "name": "Chicago Ctr for Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brookline", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02445"
                    }, 
                    "name": "Community Research Initiative of New England"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10011"
                    }, 
                    "name": "Saint Vincent's AIDS Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38104"
                    }, 
                    "name": "Methodist Hosp"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase III Trial to Evaluate the Safety and Antiviral Efficacy of 141W94 in Combination With Retrovir and Epivir Compared to Retrovir and Epivir Alone in Patients With HIV Infection.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002195"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Glaxo Wellcome", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 1998"
    }, 
    "geocoordinates": {
        "Chicago Ctr for Clinical Research": "41.878 -87.63", 
        "Community Research Initiative of Central Florida": "28.628 -81.363", 
        "Community Research Initiative of New England": "42.332 -71.121", 
        "Community Research Initiative of South Florida": "25.721 -80.268", 
        "Dr Bruce Rashbaum": "38.895 -77.036", 
        "Methodist Hosp": "35.15 -90.049", 
        "Pacific Oaks Research": "34.074 -118.4", 
        "Saint Vincent's AIDS Ctr": "40.714 -74.006", 
        "Univ of Miami School of Medicine": "25.789 -80.226"
    }
}